Changes to the Code
H.R. 9418 · Access to Innovative Treatments Act of 2026 · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
In committee · step 2 of 5
42 U.S.C. § 1395w–102 Prescription drug benefits
1 change the bill asks for here, 1 carried out
- Carried out:
Section 1860D–2(e)(3) of the Social Security Act (42 U.S.C. 1395w–102(e)(3)) is amended by adding at the end the following new sentence:
In determining whether payment would not be made with respect to a covered part D drug if section 1862(a) applied to this part, a prescription drug plan or MA–PD plan may not base such determination on a national coverage determination made with respect to such drug if such determination is a specified national coverage determination (as defined in section 1862(l)(5)).
.
§ 1395w–102(e)Covered part D drug defined(3)–(4)
Start of § 1395w–102 to (e)(3) unchanged ·
(A) for which payment would not be made if section 1395y(a) of this title applied to this part; or
(B) which is not prescribed in accordance with the plan or this part.
Such exclusions are determinations subject to reconsideration and appeal pursuant to subsections (g) and (h), respectively, of section 1395w–104 of this title.[inserted: In determining whether payment would not be made with respect to a covered part D drug if section 1862(a) applied to this part, a prescription drug plan or MA–PD plan may not base such determination on a national coverage determination made with respect to such drug if such determination is a specified national coverage determination (as defined in section 1862(l)(5)).]
(4) Medically accepted indication defined
(A) In general For purposes of paragraph (1), the term “medically accepted indication” has the meaning given that term—
Rest of § 1395w–102 unchanged ·
42 U.S.C. § 1395y Exclusions from coverage and medicare as secondary payer
2 changes the bill asks for here, 2 carried out
- Carried out:
by redesignating paragraphs (5) and (6) as paragraphs (7) and (8), respectively; and
- Carried out:
by inserting after paragraph (4) the following new paragraphs:
(5) Review of national coverage determinations for drugs and biologicals.— (A) In general.— Subject to subparagraph (D), not later than 90 days after receiving a request for a review of a specified national coverage determination (as defined in subparagraph (E)), the Secretary …
§ 1395y(l)–(m)
Start of § 1395y to (l)(3)(C)(iii) unchanged ·
(iv) in the case of a final decision under clause (i) to grant the request for the national coverage determination, the Secretary shall assign a temporary or permanent code (whether existing or unclassified) and implement the coding change.
(4) Consultation with outside experts in certain national coverage determinations With respect to a request for a national coverage determination for which there is not a review by the Medicare Coverage Advisory Committee, the Secretary shall consult with appropriate outside clinical experts.
(5) [inserted: Review of national coverage determinations for drugs and biologicals.—]
(A) [inserted: In general.—] [inserted: Subject to subparagraph (D), not later than 90 days after receiving a request for a review of a specified national coverage determination (as defined in subparagraph (E)), the Secretary shall initiate such a review in accordance with the provisions of this paragraph.]
(B) [inserted: Public comment period.—] [inserted: Beginning on the date of the initiation of a review of a specified national coverage determination under subparagraph (A), the Secretary shall provide for a 30-day public comment period as to whether such determination should be affirmed, reversed, or otherwise modified.]
(C) [inserted: Final decision.—] [inserted: Not later than 120 days after the conclusion of the 30-day period described in subparagraph (B) with respect to a specified national coverage determination, the Secretary shall—]
(i) [inserted: make a final decision as to whether such determination should be affirmed, reversed, or otherwise modified;]
(ii) [inserted: include in such final decision summaries of the public comments received and responses to such comments;]
(iii) [inserted: make available to the public the clinical evidence and other data used in making such decision when such decision differs from the recommendations of the Medicare Coverage Advisory Committee; and]
(iv) [inserted: in the case of a final decision under clause (i) to reverse or modify such determination, the Secretary shall assign a temporary or permanent code (whether existing or unclassified) and implement the coding change as applicable.]
(D) [inserted: Limitation on successive reviews.—] [inserted: Subparagraph (A) shall not apply with respect to a request for a review of a specified national coverage determination if the Secretary has made a final decision with respect to a previous review of such determination under this paragraph during the 2-year period ending on the date of the receipt of such request. Nothing in the preceding sentence shall be construed to limit the authority of the Secretary to review or reconsider a national coverage determination if determined appropriate by the Secretary.]
(E) [inserted: Specified national coverage determination defined.—] [inserted: In this paragraph, the term “specified national coverage determination” means a national coverage determination made with respect to a drug or biological approved under section 505(c) of the Federal Food, Drug, and Cosmetic Act or licensed under section 351 of the Public Health Service Act under which coverage of such drug or biological under this title was denied or otherwise limited in a manner inconsistent with such approval or licensure.]
(6) [inserted: Prohibition on application of certain existing national coverage determinations to newly approved drugs and biologicals.—] [inserted: The Secretary may not, with respect to a drug approved under section 505(c) of the Federal Food, Drug, and Cosmetic Act or a biological licensed under section 351 of the Public Health Service Act, apply a national coverage determination that was made prior to the date of such approval or licensure (as applicable) to the extent that such application would result in a denial or other limit of coverage under this title for such drug or biological in a manner inconsistent with such approval or licensure.]
[struck: (5)] [inserted: (7)] Local coverage determination process
(A) Plan to promote consistency of coverage determinations The Secretary shall develop a plan to evaluate new local coverage determinations to determine which determinations should be adopted nationally and to what extent greater consistency can be achieved among local coverage determinations.
(B) Consultation The Secretary shall require the fiscal intermediaries or carriers providing services within the same area to consult on all new local coverage determinations within the area.
(C) Dissemination of information The Secretary should serve as a center to disseminate information on local coverage determinations among fiscal intermediaries and carriers to reduce duplication of effort.
(D) Local coverage determinations The Secretary shall require each Medicare administrative contractor that develops a local coverage determination to make available on the Internet website of such contractor and on the Medicare Internet website, at least 45 days before the effective date of such determination, the following information:
(i) Such determination in its entirety.
(ii) Where and when the proposed determination was first made public.
(iii) Hyperlinks to the proposed determination and a response to comments submitted to the contractor with respect to such proposed determination.
(iv) A summary of evidence that was considered by the contractor during the development of such determination and a list of the sources of such evidence.
(v) An explanation of the rationale that supports such determination.
[struck: (6)] [inserted: (8)] National and local coverage determination defined For purposes of this subsection—
(A) National coverage determination The term “national coverage determination” means a determination by the Secretary with respect to whether or not a particular item or service is covered nationally under this subchapter.
(B) Local coverage determination The term “local coverage determination” has the meaning given that in section 1395ff(f)(2)(B) of this title.
(m) Coverage of routine costs associated with certain clinical trials of category A devices
(1) In general In the case of an individual entitled to benefits under part A, or enrolled under part B, or both who participates in a category A clinical trial, the Secretary shall not exclude under subsection (a)(1) payment for coverage of routine costs of care (as defined by the Secretary) furnished to such individual in the trial.
Rest of § 1395y unchanged ·